Newmark Names Elizabeth Berthelette, CRE, as Head of National Life Science Research

Elizabeth Berthelette

New York, NY — Newmark announced that Elizabeth Berthelette, CRE, has been promoted, expanding her oversight from Head of Northeast Research to encompass the newly created Head of National Life Science Research role.

Reporting to Executive Managing Director of National Research Jonathan Mazur, Berthelette will collaborate with Research along with Capital Markets and Brokerage professionals to provide data in high concentration Life Science markets across the United States.

“Liz’s meticulous approach will be instrumental as Newmark further expands our Life Science Research,” said Executive Managing Director of Global Research David Bitner. “As an analytical and highly knowledgeable researcher, Liz’s expanded role will benefit Newmark and our clients.”

Working alongside Newmark’s Life Science Capital Markets Practice Group, with a concentration on the country’s most dynamic life sciences markets, Berthelette will oversee Life Science data pertaining to employment, strength of local markets, supply/demand balance, new construction, build out costs, vacancies, investment sales activity and debt financing. Additionally, beyond real estate, Berthelette will provide insights on Life Science market demand drivers such as population, healthcare costs, manufacturing, funding and public markets.

“Her nuanced expertise infuses value to nearly every initiative we have going in Newmark’s Research platform,” said Mazur.

With over 16 years of experience providing insights, Berthelette previously served as Director of Research for Newmark’s Boston office. Prior to joining Newmark, Berthelette held senior research positions at Hunneman and Colliers International.

Rapid growth within the U.S. life science industry over the last several years has resulted in a very healthy development pipeline, outsized rent growth, historically low vacancies and record levels of investment. More capital, both public and private, flowed into the life science sector from 2020 to 2021 than at any point in U.S. history and long-term growth drivers remain decidedly positive.